Mainz Biomed Provides Half Year 2024 Corporate Update

Core Insights - Mainz Biomed N.V. has made significant progress in the first half of 2024, driven by strong clinical results from three studies, and is preparing for the enrollment planning of the ReconAAsense U.S. FDA pivotal CRC study [3][6] Company Highlights - Mainz Biomed's pooled study presented at ASCO 2024 confirmed high sensitivity rates for colorectal cancer (CRC) detection: 92% for CRC and 82% for advanced adenomas, with 95.8% detection of high-grade dysplasia [6] - The company received a Poster of Distinction at Digestive Disease Week for its eAArly DETECT study, showcasing 97% sensitivity for CRC and 100% detection of high-grade dysplasia among advanced precancerous lesions [6] - Mainz Biomed participated in the 39th UDH Congress 2024, focusing on the gut's role in disease manifestation, and exhibited at the Gynecology Congress in Stuttgart, emphasizing the importance of gynecologists in early CRC detection [6] - The company is advancing its U.S. go-to-market strategy for its ColoAlert® diagnostic test through partnerships with Trusted Health Advisors and TomaLab, enhancing colorectal cancer screening in the U.S. and Italy respectively [6][8] Industry Context - Colorectal cancer is the third most common cancer globally, with over 1.9 million new cases reported in 2020 [3] - The U.S. Preventive Services Task Force recommends stool DNA tests like ColoAlert® every three years starting at age 45, highlighting a significant market opportunity of over $4.0 billion due to the screening gap among U.S. residents aged 50-75 [7]